The NM_000152.5:c.1903A>G variant in GAA is predicted to result in a missense substitution from asparagine to aspartate at amino acid 635 (p.Asn635Asp). The variant has been identified in at least 3 probands, all identified by positive newborn screen, with confirmatory GAA activity in dried blood spot of 1.0, 1.3, and 1.34 pmol/punch/hour (affected range <3.88); pseudodeficiency variants are confirmed to be absent (Clinical Diagnostic Laboratory, PMID: 37087815) (PP4_Moderate). Each of these individuals is compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP, either c.2238G>C (p.Trp746Cys), c.2560C>T (p.Arg854Ter), and c.-32-13T>G; phase not confirmed (Clinical diagnostic laboratory) (PM3). The highest population minor allele frequency in gnomAD v4.0. is 0.000003602 (4/1110350 alleles) in the European non-Finnish population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.518 which is neither above nor below the thresholds predicting a damaging (>0.7) or benign (<0.5) impact on GAA function. Another missense variant at the same amino acid position, c.1905C>A (p.Asn635Lys), has been reported in four Brazilian probands with Pompe disease (PMID: 19588081) and has been classified as likely pathogenic by the ClinGen LD VCEP (PM5_Supporting). There is a ClinVar entry for this variant (Variation ID: 1348299). In summary, this variant meets the criteria to e classified as likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM3, PP4_Moderate, PM2_Supporting, PM5_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 20, 2023).